Every material Form 8-K Yarrow Bioscience, Inc. has filed with the SEC since July 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Yarrow Bioscience entered an underwriting agreement on September 10, 2026, to sell 5,769,231 common shares at $26.00 per share, and the underwriters exercised in full their option to buy 865,384 more shares on September 11, 2026. The company expects net proceeds of about $161.8 million, with closing expected on September 14, 2026. The sale adds new shares outstanding, which dilutes existing shareholders, and directors and executive officers agreed to a 60-day lock-up on selling their shares.
Base offering of 5,769,231 shares at $26.00 per share, underwritten by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC
Underwriters exercised in full their 30-day option on September 11, 2026, for up to 865,384 additional shares
Expected net proceeds of about $161.8 million after underwriting discounts and estimated offering expenses
Offering made under a Form S-3 shelf registration effective August 19, 2026; closing expected September 14, 2026; directors and executive officers subject to a 60-day lock-up
Yarrow Bioscience filed an 8-K on September 10, 2026, furnishing a September 2026 investor presentation and an update to the Business section of its 2025 Form 10-K to reflect its merger with Yarrow Bioscience Operating Company Corp. The company states the revisions have no effect on previously reported results, financial position, or cash flows, and the presentation says the company's cash resources are expected to fund operations into 2028.
Investor presentation dated September 2026 made available on September 10, 2026 (Exhibit 99.1)
Business update reflects the merger with Yarrow Bioscience Operating Company Corp. (formerly Yarrow Bioscience, Inc.); company states no effect on previously reported results
Presentation cites $200 million raised to date and cash runway expected into 2028
Phase 2a readout for YB-101 in Graves' disease anticipated in 2H 2027
On July 29, 2026, Yarrow Bioscience closed an exchange in which an existing stockholder swapped 133,290 shares of common stock for pre-funded warrants to buy the same number of shares at $0.0001 per share. After the exchange, the company has 2,669,788 common shares and pre-funded warrants for 25,914,530 shares outstanding, so the potential future share count is far larger than the common shares currently outstanding. Shareholders may care because those warrants could add to the number of shares outstanding if exercised.
Exchange closed July 29, 2026: 133,290 common shares exchanged for pre-funded warrants at a $0.0001 exercise price
Pre-funded warrants are immediately exercisable and can be exercised in full, subject to a 9.99% beneficial ownership limit
Limit may be raised or lowered up to 19.99% on 61 days' notice to the company
After the exchange: 2,669,788 common shares and pre-funded warrants for 25,914,530 shares outstanding
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Yarrow Bioscience, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →